Wuxi Biologics (Cayman) Inc. (DE:1FW2)

FRANKFURT:1FW2

1FW2

Wuxi Biologics (Cayman)

RESEARCH TOOLSreports

Wuxi Biologics (Cayman) (1FW2) Price & Analysis

4 Followers

1FW2 Stock Chart & Stats

€3.85

€0.01(0.50%)

At close: Jan 08 4:00 PM EST

€3.85

€0.01(0.50%)

Day’s Range― - ―

52-Week Range€2.63 - €4.68

Previous CloseN/A

Volume1.00K

Average Volume (3M)1.95K

Market Cap

€14.87B

Enterprise Value€113.09B

Total Cash (Recent Filing)€15.74B

Total Debt (Recent Filing)€3.11B

Price to Earnings (P/E)24.1

Beta0.91

Next Earnings

Aug 26, 2026

EPS Estimate

0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.19

Shares Outstanding4,141,014,600

10 Day Avg. Volume2,439

30 Day Avg. Volume1,954

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)2.53

Price to Sales (P/S)5.48

P/FCF Ratio42.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€4.97

Price Target Upside29.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)0.15

Revenue Forecast (FY)€2.77B

Bulls Say, Bears Say

Bulls Say

Strong Profitability And MarginsSustained high gross and operating margins indicate durable operational strength and pricing power across biologics services. Higher margins support reinvestment in capacity and R&D, provide cushion against pricing pressure, and underpin long-term free cash generation potential.

Conservative Balance Sheet With Low LeverageVery low and falling leverage gives the company financial flexibility to fund capacity expansion or absorb cyclical shocks without stressing liquidity. This durability lowers refinancing risk and supports strategic investments that sustain long-term competitive positioning.

Integrated End-to-end CRDMO PlatformAn end-to-end CRDMO model creates client stickiness and cross-sell opportunities as programs move from discovery to commercial supply. Consolidation benefits drive longer-duration contracts and recurring manufacturing revenue, supporting predictable scale and margin durability over time.

Bears Say

Slowing Revenue GrowthA marked deceleration in top-line growth reduces the pace at which scale economies and fixed-cost absorption can improve returns. If the slowdown persists, capacity utilization, pricing leverage and long-term revenue visibility could be constrained, weakening future margin expansion.

Weak Cash Conversion And FCF VolatilityAlthough free cash flow improved in 2025, conversion remains well below earnings and earlier years saw negative FCF. This indicates sensitivity to capex and working capital; inconsistent cash conversion can limit self-funded growth, dividend flexibility, and balance sheet resilience.

Returns Still Below Prior Peak LevelsROE and margins have improved but remain shy of earlier peaks, suggesting competitive, mix, or cost pressures versus prior cycles. Sustained lower returns could signal structural limits on profitability and cap the firm's ability to deliver superior long-term capital returns.

Wuxi Biologics (Cayman) News

WuXi Biologics Schedules 2026 Business Update Calls for Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has announced that it will host...

5d ago

WuXi Biologics Launches US$400 Million Share Buyback Plan

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an update. WuXi Biologics has resolved to activate its shareholder-approved...

11d ago

WuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate

The latest update is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). WuXi Biologics (Cayman) Inc. has called...

17d ago

WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating

CMB International Securities analyst Jill Wu maintained a Buy rating on Wuxi Biologics (Cayman) today and set a...

2M ago

Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has approved the grant of 25,575,356...

2M ago

WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an announcement. WuXi Biologics (Cayman) Inc., a Hong Kong-listed biologics...

2M ago

Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. Wuxi Biologics reported strong 2025 results, with revenue...

2M ago

WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an update. WuXi Biologics (Cayman) Inc. has issued a positive...

4M ago

WuXi Biologics Sets March 24 Board Meeting to Approve 2025 Annual Results

An update from Wuxi Biologics (Cayman) ( ($HK:2269) ) is now available. WuXi Biologics (Cayman) Inc. has scheduled...

4M ago

WuXi Biologics’ Substantial Shareholder to Cut Stake via HK$38.52 Block Trade

Wuxi Biologics (Cayman) ( ($HK:2269) ) just unveiled an announcement. WuXi Biologics announced that substantial shareholder WuXi Biologics...

5M ago

WuXi Biologics downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50....

2y ago

GSK, WuXi Biologics enter into license agreement on TCE antibodies

WuXi Biologics (WXIBF) announced a license agreement with GSK plc (GSK) under which GSK will have exclusive licenses...

3y ago

GSK

1FW2 FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?

Wuxi Biologics (Cayman) Inc. lowest stock price was €2.63 and its highest was €4.68 in the past 12 months.

What is Wuxi Biologics (Cayman) Inc.’s market cap?

Wuxi Biologics (Cayman) Inc.’s market cap is €14.87B.

When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?

Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 26, 2026 which is in 82 days.

How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?

Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 24, 2026. The company reported €0.075 earnings per share for the quarter, missing the consensus estimate of €0.08 by -€0.005.

Is Wuxi Biologics (Cayman) Inc. overvalued?

According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wuxi Biologics (Cayman) Inc. pay dividends?

Wuxi Biologics (Cayman) Inc. does not currently pay dividends.

What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?

Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.07.

How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?

Wuxi Biologics (Cayman) Inc. has 4,141,014,600 shares outstanding.

What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?

Wuxi Biologics (Cayman) Inc. reported an EPS of €0.075 in its last earnings report, missing expectations of €0.08. Following the earnings report the stock price went up 4.784%.

Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?

Currently, no hedge funds are holding shares in DE:1FW2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wuxi Biologics (Cayman) Stock Smart Score

Outperform

Fundamentals

Return on Equity

10.64%

Trailing 12-Months

Asset Growth

16.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wuxi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Wuxi Biologics (Cayman) (1FW2) Earnings & Revenues

Historic Earnings Reports

1FW2 Company Deck

1FW2 Earnings Call

Q4 2026

0:00 / 0:00

1FW2 Stock 12 Month Forecast

Average Price Target

€4.97

▲(29.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","6":"€6","2.25":"€2.25","3.5":"€3.5","4.75":"€4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.97608177,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.970837330833333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.057901,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.75,3.9212370592307693,4.0924741184615385,4.263711177692308,4.434948236923077,4.606185296153846,4.777422355384616,4.948659414615385,5.119896473846154,5.291133533076923,5.462370592307693,5.633607651538462,5.804844710769231,{"y":5.97608177,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.75,3.8439105639102564,3.937821127820513,4.031731691730769,4.125642255641026,4.219552819551282,4.313463383461539,4.407373947371795,4.5012845112820505,4.595195075192307,4.689105639102563,4.78301620301282,4.876926766923076,{"y":4.970837330833333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.75,3.7736846923076923,3.7973693846153846,3.821054076923077,3.8447387692307693,3.8684234615384616,3.892108153846154,3.9157928461538463,3.9394775384615386,3.963162230769231,3.9868469230769232,4.0105316153846156,4.034216307692308,{"y":4.057901,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.731,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.329,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.833,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.414,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.465,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.208,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >